ALETA-001, a CAR-T Engager protein, or CTE, optimizes anti-CD19 CAR-T celltherapies for lymphoma

Publication
Written By Rhodesia Jackson
Rhodesia Jackson

I am a designer, web developer, & closeted nerd.

I’m also an avid reader, plant lover (and killer), and wannabe interior decorator. I’m all about self-care, from yoga to DIY facials. For now, Boston is my home, but I have dreams to travel the world.

I have been designing for over 10 years and I’ve worked with large financial technology software firms to yoga teachers. Although I worked in the corporate world for the beginning of my career, my true passion lies in helping entrepreneurs develop their own bold, beautiful brand identities and websites.

https://rhodesiajdesigns.com
Previous

Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001
Next

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001